SR-016 is under clinical development by Suzhou Ribo Life Sciences and currently in Phase I for Hepatitis B. According to GlobalData, Phase I drugs for Hepatitis B have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SR-016’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SR-016 overview

SR-016 is under development for the treatment of Hepatitis B. The drug candidate is a siRNA (small interference RNA). The drug candidate is administered by subcutaneous route. It is delivered using RBP131 which is a liposomal nanoparticle for liver-targeted systemic delivery of siRNA.

Suzhou Ribo Life Sciences overview

Suzhou Ribo Life Sciences (Ribo) is a drug development company that develops nucleic acid drugs and related products based on the RNA interference (RNAi) technology. The company’s pipeline products include QPI-1007, RB-RQ007, RB-T2D003, RB-PCA006, RB-AG010 and others. Ribo also develops RBP131, a lipid nanoparticle based and liver-targeted delivery system for systemic delivery siRNA drug. The company’s RNAi platform develops biomedicine and is capable of “silencing” genes specifically using RNAi. Ribo is headquartered in Kunshan, Jiangsu, China.

For a complete picture of SR-016’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.